Intestinal elimination of albendazole sulfoxide: Pharmacokinetic effects of inhibitors

International Journal of Pharmaceutics

Volumn 263, Issue 1-2, 2003, Pages 123-132

  Merino, Gracia ^a   Molina, Antonio J ^a   García, José L ^a   Pulido, Mivis M ^a   Prieto, Julio G ^a   Álvarez, Ana I ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

Albendazole sulfoxide; Drug interactions; Enantiomers; Intestinal elimination

Indexed keywords

ALBENDAZOLE; ALBENDAZOLE SULFOXIDE; AMPICILLIN; ANTHELMINTIC AGENT; CYCLOSPORIN; GLUCOSE; IVERMECTIN; KETOCONAZOLE; OXFENDAZOLE; QUINIDINE; SODIUM CHLORIDE; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SHEEP; SMALL INTESTINE; STATISTICAL ANALYSIS; STEREOCHEMISTRY;

EID: 0042383336     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00369-7     Document Type: Article

References (38)

1. Alvinerie M., Dupuy J., Eeckhoutte C., Sutra J.F. Enhanced absorption of pour-on ivermectin formulation in rats by coadministration of the multidrug-resistance-reversing agent verapamil. Parasitol. Res. 85:1999;920-922.
2. Bennett A., Guyatt H. Reducing intestinal nematode infection: efficacy of albendazole and mebendazole. Parasitol. Today. 16:2000;71-74.
3. Berrozpe, J.D., Lanas, J.M., Pla Delfina, J.M., 1997. Biofarmacia y Farmacocinética, vol. 1. Editorial Síntesis S.A., Madrid.
4. Costa S.F., Weiss L.M. Drug treatment of microsporidiosis. Drug Resist. Updat. 3:2000;384-399.
5. Cox F.E.G. Elimination of lymphatic filariasis as a public health problem. Parasitol. Today. 16:2000;135.
6. Dantzig A.H., de Alwis D.P., Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Deliv. Rev. 55:2003;133-150.
7. Dautrey S., Felice K., Petiet A., Lacour B., Carbon C., Farinotti R. Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates. Br. J. Pharmacol. 127:1999;1728-1734.
8. Delatour P., Benoit E., Besse S., Boukraa A. Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs and rats. Xenobiotica. 21:1991;217-221.
9. Farrier, D.S., 1997. PK Solutions (version 2.0.2.): a Noncompartmental Pharmacokinetic Data Analysis Program. Summit Research Services, 1374 Hillcrest Drive, Ashland, OH, USA.
10. Fromm M.F., Busse D., Kroemer H.K., Eichelbaum M. Diferential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology. 24:1996;796-801.
11. Galtier P., Alvinerie M., Delatour P. In vitro sulfoxidation of albendazole by ovine liver microsomes. Am. J. Vet. Res. 47:1986;447-450.
12. Gan L.S., Moseley A., Khosla B., Augustijns P., Bradshaw T., Hendren W., Thakker D. Formation and polarized efflux of cyclosporin A metabolites in the in vitro Caco-2 cell culture. FASEB J. 9:1995;A367.
13. Gramatte T., Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin. Pharmacol. Ther. 66:1999;239-245.
14. Hanafy A., Langguth P., Spahn-Langguth H. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Eur. J. Pharm. Sci. 12:2001;405-415.
15. Hill G., Cihlar T., Oo C., Ho E.S., Prior K., Wiltshire H., Barrett J., Liu B., Ward P. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetics drug interactions via renal secretion-correlation on in vivo and in vitro studies. Drug Metab. Dispos. 30:2002;13-19.
16. Kumar S., Riggs K.W., Rurak D.W. Role of the liver and gut in systemic diphenhydramine clearance in adult nonpregnant sheep. Drug Metab. Dispos. 27:1999;297-302.
17. Laffont C.M., Toutain P.L., Alvinerie M., Bousquet-Mélou A. Intestinal secretion is a major route for parent ivermectin elimination in rat. Drug Metab. Dispos. 30:2002;626-630.
18. Lin J.H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 55:2003;53-81.
19. Lin J.H., Chiba M., Baillie T.A. Is the role of the small intestine in first-pass metabolism overemphasized? Pharm. Rev. 51:1999;135-157.
20. Merino G., Alvarez A.I., Prieto J.G., Kim R.B. The anthelmintic agent albendazole does not interact with P-glycoprotein. Drug Metab. Dispos. 30:2002;365-369.
21. Molento M.B., Prichard R.K. Effects of the multidrug resistance-reversing agents verapamil and CL 347,099 on the efficacy of ivermectin or moxidectin against unselected and drug-selected strains of Haemonchus contortus in gerbils (Meriones unguiculatus). Parasitol. Res. 85:1999;1007-1011.
22. Moroni P., Buronfosse T., Longin-Sauvageon C., Delatour P., Benoit E. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes. Drug Metab. Dispos. 23:1995;160-165.
23. Pourgholami M.H., Woon L., Almajd R., Akhter J., Bowery P., Morris D.L. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett. 165:2001;43-49.
24. Rabbaa L., Dautrey S., Colas-Linhart N., Carbon C., Farinotti R. Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process. Antimicrob. Agents Chemother. 36:1996;2506-2511.
25. Rawden H.L., Kokwaro G.O., Ward S.A., Edwards G. Relative contribution of cytochromes P450 and flavin-containing monooxygenases to the metabolism of albendazole by human liver microsomes. Br. J. Clin. Pharmacol. 49:2000;313-322.
26. Redondo P.A., Alvarez A.I., García J.L., Villaverde C., Prieto J.G. Influence of surfactants on oral bioavailability of albendazole based on the formation of the sulphoxide metabolites in rats. Biopharm. Drug Dispos. 19:1998;65-70.
27. Redondo P.A., Alvarez A.I., García J.L., Larrode O.M., Merino G., Prieto J.G. Presystemic metabolism of albendazole: experimental evidence of an efflux process of albendazole sulfoxide to intestinal lumen. Drug Metab. Dispos. 27:1999;736-740.
28. Rolin S., Souhaili El Amri H., Batt A.M., Levy M., Bagrel D., Siest G. Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatoma cell lines. Cell Biol. Toxicol. 5:1989;1-13.
29. Saitoh H., Gerard C., Aungst B. The secretory intestinal transport of some beta-lactam antibiotics and anionic compounds: a mechanism contributing to poor oral absorption. J. Pharmacol. Exp. Ther. 278:1996;205-211.
30. Souhaili-El Amri H., Mothe O., Totis M., Masson C., Batt A.M., Delatour P., Siest G. Albendazole sulfonation by rat liver cytochrome P-450c. J. Pharmacol. Ther. 246:1988;758-764.
31. Spahn-Langguth H., Baktir G., Radschuwert A., Okyar A., Terhaag B., Ader P., Hanafi A., Langguth P. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36:1998;16-24.
32. Synold T.W., Dussault I., Forman B.M. The orphan nuclear receptor SXR co-ordinately regulates drug metabolism and efflux. Nat. Med. 7:2001;584-590.
33. Terao T., Hisanaga E., Sai Y., Tamai I., Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol. 48:1996;1083-1089.
34. Tsai T.H. Effect of ivermectin on the disposition of amoxicillin in rat blood and brain using microdialysis sampling. Anal. Chim. Acta. 431:2001;279-285.
35. Villaverde C., Alvarez A.I., Redondo P., Voces J., del Estal J.L., Prieto J.G. Small intestinal sulphoxidation of albendazole. Xenobiotica. 25:1995;433-441.
36. Wacher V.J., Salphati L., Benet L.Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46:2001;89-102.
37. Zhu B.T. A novel hypothesis for the mechanism of action of P-glycoprotein as a multidrug transporter. Mol. Carcinog. 25:1999;1-13.
38. Zulu I., Veitch A., Sianongo S., McPhail G., Feakins R., Farthing M.J.G., Kelly P. Albendazole chemotherapy for AIDS-related diarrhoea in Zambia-clinical, parasitological and mucosal responses. Aliment. Pharmacol. Ther. 16:2002;595-601.